Weight loss is more than a number: the metabolic health changes that matter
Updated: Oct 1
Why the scale gets too much attention
Body weight is easy to measure, which makes it attractive as the headline result. But obesity is clinically important because of its relationship with conditions such as type 2 diabetes, hypertension, dyslipidaemia, sleep apnoea and cardiovascular disease.
A treatment plan should therefore connect weight change to health outcomes.
Waist circumference can add information
Abdominal excess weight is particularly relevant to metabolic risk, including in Indian populations. A reduction in waist circumference can therefore provide useful information that the scale alone cannot.
In SURMOUNT-5, for example, waist circumference was a prespecified outcome alongside weight.
Blood sugar and diabetes risk
GLP-1-based medicines originated in diabetes care because of their effects on glucose regulation. In patients with type 2 diabetes or dysglycaemia, HbA1c and other glycaemic measures may be clinically meaningful outcomes.
Changes should be interpreted alongside any other diabetes medicines because treatment may need adjustment.
Blood pressure and lipids
Weight reduction and broader metabolic changes can be accompanied by improvements in blood pressure and lipid measures in some patients. These are relevant because cardiovascular risk is built from multiple factors rather than weight alone. The effect varies by patient and should not be promised as an automatic outcome.
Cardiovascular outcomes: an important example
The SELECT trial studied semaglutide 2.4 mg in adults with overweight or obesity and established cardiovascular disease but without diabetes. It demonstrated a reduction in major adverse cardiovascular events in that specific high-risk population.
This is important evidence, but it should not be simplified into 'all GLP-1s prevent heart attacks for everyone'. The exact medicine and study population matter.
Health should remain the endpoint
Weight can be an important treatment target, but a patient is not a percentage on a scale. Better care asks whether treatment is improving risk, function, confidence in healthy behaviours and the ability to sustain a healthier life.
That is the broader conversation an evidence-led obesity program should keep returning to.
References:
Ross R, et al. Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity. Nature Reviews Endocrinology. 2020. DOI: 10.1038/s41574-019-0310-7. PubMed
Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023. DOI: 10.1056/NEJMoa2307563. PubMed
Endocrine Society of India. Clinical Practice Guidelines for the Evaluation and Management of Obesity in India: 2025 Update.
Written and clinically reviewed by: Dr Saran Seker, MBBS (Aus), Chief Medical Officer
Last reviewed: September 2026
Comments